Matthias Gromeier, MD

Professor of Neurosurgery
Professor in Molecular Genetics and Microbiology
Professor in Medicine
Member of the Duke Cancer Institute
Campus mail Box 3020 Med Ctr, Durham, NC 27710
Phone (919) 668-6205
Email address grome001@mc.duke.edu

I am a classically trained virologist with a focus on molecular mechanisms of RNA virus pathogenesis. My career is dedicated to unraveling RNA virus:host relations and devising methods of exploiting them for cancer immunotherapy and vaccine design. My background is in translation regulation and mRNA metabolism, viral RNA sensing and innate immunity, and cancer immunology and immunotherapy. Basic mechanistic research in my laboratory is supporting an ambitious clinical translational research program with active multi-center clinical trials in several cancer indications. 

Education and Training

  • Postdoctoral Associate, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1996 - 1999
  • Postdoctoral fellow, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1993 - 1996
  • M.D., University of Hamburg (Germany), 1992

Publications

Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Jason Watts, Stevie Threatt, et al. “Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2106–TPS2106. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2106.

Full Text

Dobrikov, Mikhail I., Mayya Shveygert, Michael C. Brown, and Matthias Gromeier. “Mitotic phosphorylation of eukaryotic initiation factor 4G1 (eIF4G1) at Ser1232 by Cdk1:cyclin B inhibits eIF4A helicase complex binding with RNA.” Mol Cell Biol 34, no. 3 (February 2014): 439–51. https://doi.org/10.1128/MCB.01046-13.

PMID
24248602
Full Text

Desjardins, Annick, John Sampson, Katherine Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Herndon, et al. “PHASE 1 STUDY OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 15:107–8. OXFORD UNIV PRESS INC, 2013.

Scholars@Duke

Barton, Kelly, Katie Misuraca, Francisco Cordero, Elena Dobrikova, Hooney Min, Matthias Gromeier, David Kirsch, and Oren Becher. “PD-0332991, A CDK4/6 INHIBITOR, SIGNIFICANTLY PROLONGS SURVIVAL IN A GENETICALLY ENGINEERED MOUSE MODEL OF BRAINSTEM GLIOMA.” In Neuro Oncology, 15:38–38. OXFORD UNIV PRESS INC, 2013.

Scholars@Duke

Sampson, J. H., A. Desjardins, K. B. Peters, T. Ranjan, G. Vlahovic, D. Lally-Goss, S. Threatt, et al. “107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” Neurosurgery 60 Suppl 1 (August 2013): 155. https://doi.org/10.1227/01.neu.0000432699.02392.a4.

PMID
23839374
Full Text

Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.

Scholars@Duke

Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31, 2013.

Scholars@Duke

Chandramohan, V., D. A. Mitchell, M. Gromeier, J. H. Sampson, and D. D. Bigner. “Current immunotherapeutic targets in gliomas,” May 1, 2013, 287–305.

Scholars@Duke

Gromeier, Matthias, Annick Desjardins, John H. Sampson, Stevie J. E. Threatt, James E. Herndon, Allan Friedman, Henry S. Friedman, and Darell D. Bigner. “ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS.” In Neuro Oncology, 15:20–20. OXFORD UNIV PRESS INC, 2013.

Scholars@Duke

Dobrikov, Mikhail I., Elena Y. Dobrikova, and Matthias Gromeier. “Dynamic regulation of the translation initiation helicase complex by mitogenic signal transduction to eukaryotic translation initiation factor 4G.” Mol Cell Biol 33, no. 5 (March 2013): 937–46. https://doi.org/10.1128/MCB.01441-12.

PMID
23263986
Full Text

Pages